The Pruritus NRS measures how bad your itching is using a scale of 0 (no itch) to 10 (worst itch). In both ADvocate trials, a significantly larger percentage of people had an IGA response in the ...

All three doses significantly reduced peak pruritus scores versus placebo, including patients with baseline PP-NRS ≥3 or ≥4. The most common treatment-emergent adverse events (TEAEs ...

Outcomes included Peak Pruritus Numerical Rating Scale (PP-NRS), 5-level itch scale, Investigator’s Global Assessment (IGA), number of PN nodules, Insomnia Severity Index (ISI), Dermatology Life ...

Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June ...

Published reports on placebo-controlled clinical trials and other studies investigating the use of pure opioid antagonists for the prevention and treatment of opioid-induced pruritus (OIP ...

Nearly 95% of patients tolerated the treatment well and another 95% achieved an Investigator Global Assessment (IGA) of 0/1, 93% achieved a Peak Pruritus Numerical Rating Scale (NRS) of 0/1 ...

An oral formulation of difelikefalin meanwhile is also in development for pruritus associated with atopic ... an improvement on the 24-hour Itch NRS score after 12 weeks' treatment, it did hit ...

Faster and deeper itch relief than anti-IL-4/13 agents4 --- onset of anti-pruritus effect as early as Week 2 (SM17) vs Week 4~6 (other agents), over 90% of patients achieved NRS-4 (SM17 ...